Thioredoxin-mimetic peptide attenuates epilepsy progression and neurocognitive deficits.

ABSTRACT: Epilepsy is a chronic neurological disorder characterized by recurrent seizures, in which oxidative stress and neuroinflammation play central roles in driving disease progression and pharmacoresistance. Approximately 30-40 % of patients are resistant to current antiseizure medications, which suppress symptoms but do not prevent epilepsy development or modify its progression. There is an urgent need for therapies with true disease-modifying potential. TXM-CB3 (CB3), a thioredoxin-mimetic tripeptide, has been reported to modulate redox and inflammatory pathways. In this study, we evaluated the therapeutic potential of CB3 in preclinical models of temporal lobe epilepsy, focusing on its capacity to suppress seizures, preserve neuronal integrity, and mitigate epilepsy-associated behavioral imp

SUBMITTER: Singh PK 

PROVIDER: S-EPMC12830260 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature